Next Phase Newsletter

A private equity firm based in New York previously invested in real estate, retail, and consumer products and has recently focused on life science investment opportunities. The firm is investing from their current $300M fund and also plans to raise a $200M fund focused on life sciences and consumer products. The firm’s minimum investment begins at $5M, and the investment size depends on the stage of the targeted company. The firm primarily invests in later stage life science companies. The firm is looking for companies in North America, and would seek distribution rights in China. The firm is actively looking for investment opportunities and plans to make 4-5 new investments as soon as possible. The firm would only seek to be the lead investor and will request a board seat.

The firm is a flexible and opportunistic investor that is currently considering Therapeutics, Medical Devices, Diagnostics, and Healthcare IT companies. The firm is open to all kinds of sectors but prefers companies that are into phase I of clinical trials or later. The firm is especially interested in vaccines including flu vaccines, Hepatitis A vaccine, Hepatitis B vaccine, and any other drugs for common diseases in China. The firm has a strong preference for later stage companies with products and pipelines that can directly produce and sell in China. The firm is open to medical devices with all FDA regulatory pathways, including 510k, PMA, and software-enabled devices. The firm is open to any phases in medical devices and therapeutics with a preference for those within human data. The most important consideration is the potential market in China.

The firm considers the management team’s character and entrepreneurial spirit. Team members who speak Mandarin may be a plus.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

An investment group based in New York City is currently investing in early stage biotechnology companies and company creation from dedicated capital. These investments are typically standalone and/or syndicated with a network of investors that have invested with the firm in the past. The firm founds 1-2 companies per year by creating a company around an asset that they acquired or in-licensed. The firm also considers investments in 0-3 existing companies per year, which are typically early in the company’s development and/or follow-on investments. The firm invests globally but requires the company or development programs have a North America component.

The firm is a flexible and opportunistic investor and will consider any therapeutics area. The firm focuses on drug development and makes occasional investments in therapeutic devices. The firm focuses on clinical stage drug development opportunities, but may consider earlier stage products if the drug is a repositioning/reformulation opportunity or has some human safety data in another indication and/or territory. The firm will generally focus on single therapeutic assets and avoids diagnostics, platforms, and computational biology companies that lack any drug assets. The firm looks at any area of medicine and focuses on niche areas of medicine and smaller indications.

The firm is open to both lead and co-investing depending on the opportunity. However, typically the firm will not be a lead on a large raise. If the firm creates the company they will be a very active, hands-on investor. The firm is open to investing in very young companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A global pharmaceutical company based in Europe forms in-licensing and partnering relationships with early stage therapeutic companies worldwide. The firm also has a corporate venture group which makes equity investments in early stage companies.

The firm’s focus areas are Cardiometabolic disease, CNS, Immunology, Oncology, and Respiratory diseases. Therapeutic opportunities beyond these focus areas may be considered by the corporate venture fund or by an internal research group, which assesses very early-stage emerging areas of science. The firm considers both small molecule and biologic assets but is generally not interested in cell therapy technologies. The firm prefers to consider assets that have attained proof of concept data (in vitro or in vivo) linking the treatment’s mechanism of action to the disease process.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

An angel group based in the Midwest invests up to $200K per company in early stage opportunities. The group usually invests in 9-12 companies per year and participates in convertible rounds, as well as equity investments. The Group is not restricted to Midwest companies, as it will also consider companies throughout the U.S. As membership grows, the group expects the average investment number to increase.

The group is open to all types of life science technology including Therapeutics, Healthcare IT, medical devices, and platform technologies. The group is also indication agnostic. In medical devices, the group is only interested in those in the 510K approval pathway. In terms of stage of development, the group is interested in pre-clinical to Phase I technologies.

The group is interested in companies seeking between $500K to $3M. The group does not have management team requirements though has preference towards those with experience in the space.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A Venture Capital firm based in North Carolina is investing from a fund with over $170 million in available capital. The fund focuses on seed-stage life science companies. The firm typically invests between $2 and $4 million initially and $6M to $10M over the lifetime of the investment. Investments are generally in the form of milestone based equity tranches, however the firm also has experience in working with convertible notes. The firm is looking to make 4-6 allocations in the next 6-9 months throughout the United States, with an emphasis on leading company formations in the Southeast.

The firm is currently looking for early stage companies in the Therapeutics, Diagnostics, Medical Device and Healthcare IT spaces. In the Therapeutics space, the firm is opportunistic in terms of subsector but is most interested in indications of Ophthalmology, Cardiovascular, Pulmonary, Anti-Infectives, Metabolic Disorders, Renal Diseases, Oncology, Immunology, Dermatology, and Orphan Diseases. For companies developing therapeutics, the firm is looking for companies primarily with a lead product in preclinical trials, although they will consider companies with products having recently entered Phase I. In the Medical Device space, the firm strongly prefers that the company at least has an early prototype of their product and the firm is opportunistic in terms of medical device subsector and is open to all classes of device. For Healthcare IT investments, the firm looks only at post-revenue companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A US-based venture fund that invests only in seed and pre-seed rounds is focusing on opportunities in the healthcare sector. The firm will consider opportunities US-wide, with a particular interest in Texas, California and the Northeast.

The firm invests in very early stage companies across the healthcare innovation ecosystem, including pharma, medical devices, diagnostics, and healthcare IT. The firm is highly interested in preventative healthcare, including technologies that could prevent allergies and asthma; other areas of interest include EMR, bioinformatics, and value-based care. The firm is open to investing in any area of medicine, and has an interest in opportunities in cardiology, pulmonary diseases, diabetes, and women’s health.

The firm does not invest in companies that have already raised over $5 million in dilutive capital. The firm seeks to invest in high quality management teams, and prefers to work with experienced entrepreneurs that have a good track record in their sector.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

An investment vehicle founded by a regional government agency in China focuses on scientific research, technology transfer, and commercialization. The firm is seeking new life science technologies through investment, licensing, or research collaboration. The firm can make equity investment of up to RMB 10M (US$1.5M) from its two funds of RMB 100M (US$15M) each. The firm is currently looking for China-based opportunities and overseas teams that are Chinese-led or have representatives in China.

The firm considers across several sectors including therapeutics, medical devices, diagnostics, and digital health. Within therapeutics, the firm is interested in cancer immunotherapy and infectious diseases. The firm is also interested in Anesthesia consumables, IVF related technologies and devices, orthopedic devices, wound and trauma care (within medical devices), IVD (within diagnostics), and artificial intelligence (within digital health). The firm is seeking products that have obtained or are close to obtaining FDA approval/clearance. The firm aims to advance the project through development milestones and CFDA registration process in China.

The firm is looking for Chinese-led teams or companies that have representatives in China. In addition to financial investment, the firm can also provide incubation space and R&D support.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com